Woojin Choi joined the SK Life Science, Inc. family in the fall of 2025 as Vice President of Business Development (BD). Woojin brings a differentiated skillset and deep industry network to our leadership team with over two decades of investment banking experience from several leading global financial institutions.

As a seasoned strategic advisor, Woojin’s background spans complex domestic and cross-border M&A, in-/out-licensing of clinical programs, asset/subsidiary divestitures, equity and debt capital raising, private placements, and specialty financings. Furthermore, his professional biopharma expertise varies across therapeutic areas and modalities, as well as the application of AI/ML technologies in drug development.

The BD team that Woojin leads plays a critical role as they drive growth objectives for SK Life Science, Inc. through partnerships, strategic collaborations, and M&A. Working alongside colleagues in different function groups and geographies, the BD team will evaluate numerous projects simultaneously, carefully analyzing potential market opportunities, product/technology differentiation, and ultimate fit with our mid-/long-term portfolio strategy, among many other considerations. Moreover, the BD team embraces a “patient first” vision and is therefore keenly focused on bringing essential & innovative therapies to patients and providers around the world.

Woojin earned his Bachelor of Science in Management Science from Massachusetts Institute of Technology.